Advertisement

Topics

BeiGene (Beijing), Co., Ltd. Company Profile

14:26 EDT 21st June 2018 | BioPortfolio

BeiGene is an innovative Chinese oncology R&D company focusing on discovering, developing and commercializing targeted and immune-oncology therapeutics. With a team of 150 scientists and staff, its pipeline is comprised of novel oral small molecules and monoclonal antibodies for cancer. BeiGene Ltd. is a Cayman Islands exempted company that is an investor in and collaborator with BeiGene (Beijing), Co. Ltd. For more information, please visit our website at www.beigene.com.


News Articles [288 Associated News Articles listed on BioPortfolio]

Public ADS offering nets $710.6mm for BeiGene

BeiGene (Beijing) Co. Ltd. (immuno-oncology) netted $710.6mm through the public sale of 7.4mm American Depositary Shares (representing 96.5mm common) priced at $101 per ADS. Proceeds will support gene...

BeiGene Completes $750 Million Secondary Offering

BeiGene, a Beijing innovative cancer biotech, raised a spectacular $750 million in a secondary offering of its shares. The price of the shares ended the session 13% higher after the funding was announ...

Public ADS offering nets $758mm for BeiGene

BeiGene (Beijing) Co. Ltd. (immuno-oncology) netted $758mm through the public sale of 7.9mm American Depositary Shares (representing 103mm common; including the overallotment) priced at $101 per ADS. ...

BeiGene Launches Third Celgene Cancer Drug in China

Beijing's BeiGene has launched Vidaza® in China. Vidaza is a nucleoside metabolic inhibitor that is approved in China for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML)...

BeiGene gets exclusive rights to Mirati's sitravatinib

Mirati Therapeutics Inc. granted BeiGene (Beijing) Co. Ltd. exclusive rights to develop, manufacture, and sell the tyrosine kinase inhibitor sitravatinib in Asia (excluding Japan), Australia, and New ...

BeiGene Bags $750m, Sees China Reforms Creating New Opportunities

A spectacular secondary offering will enable Beijing-based BeiGene to expand in both novel R&D and manufacturing in 2018, driven largely...    

BeiGene to Generate New mAbs Using Harbour BioMed's Mouse Platform

Beijing's BeiGene licensed multi-year rights to use Harbour BioMed's H2L2 transgenic mouse platform, which generates fully human therapeutic monoclonal antibodies. Harbour BioMed, a Shanghai company, ...

BeiGene Acquires Asia Rights to Mirati Cancer Treatment in $133 Million Deal

BeiGene, a Beijing cancer company, in-licensed Asian rights to a clinical-stage lung cancer therapy from Mirati Therapeutics of San Diego. Sitravatinib is a spectrum-selective kinase inhibitor that ha...

Drugs and Medications [0 Results]

None

PubMed Articles [95 Associated PubMed Articles listed on BioPortfolio]

Spatio-temporal characteristics of urban air pollutions and their causal relationships: Evidence from Beijing and its neighboring cities.

China has been suffering from serious air pollution for years in response to the rapid industrialization and urbanization. Notably Beijing is one of the most polluted capitals in the world. Hence, the...

Associations between Mycobacterium tuberculosis Beijing genotype and drug resistance to four first-line drugs: A survey in China.

Investigations on the genetic diversity of Mycobacterium tuberculosis in China have shown that Beijing genotype strains play a dominant role. To study the association between the M. tuberculosis Beiji...

High myopia in Greater Beijing School Children in 2016.

To assess prevalence and associated factors of myopia and high myopia in schoolchildren in Greater Beijing.

Using big data from air quality monitors to evaluate indoor PM exposure in buildings: Case study in Beijing.

Due to time- and expense- consuming of conventional indoor PM (particulate matter with aerodynamic diameter of less than 2.5 μm) sampling, the sample size in previous studies was generally small, w...

Analysis of Hospital Charges of Inpatients with Acute Ischemic Stroke in Beijing, China, 2012-2015.

The study aimed to analyze the hospital charges of the inpatients with acute ischemic stroke in Beijing and determine the factors associated with hospital costs.

Clinical Trials [49 Associated Clinical Trials listed on BioPortfolio]

Beijing Indoor Air Health Intervention Study

The objective of this study is to investigate the cardiopulmonary health benefits from indoor air purification among school students in Beijing.

Beijing Indoor Air Purifier Intervention Study

This study aimed to assess the impact of air filtration on indoor air quality and cardio-pulmonary health in residents living in high outdoor pollution settings in Beijing.

Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in China

Anti-NMDA receptor encephalitis is the most common curable non-infectious autoimmune encephalitis,but because of the lack of recognition in the clinic, usually been misdiagnosed as other...

Beijing Hospital Atherosclerosis Study

The Beijing Hospital Atherosclerosis Study (BHAS) is a prospective, single-center, observational cohort study performed at the Beijing Hospital in Beijing, China. Subjects enrolled in this...

Trends of the Pre-hospital Emergency Care Spectrum in Beijing From 2005 to 2014: A Retrospective Analysis

This was a retrospective analysis of a cohort of all emergency care patients in Beijing from January 2005 to December 2014. This aim of this study was to analyze the trends in pre-hospital...

Companies [69 Associated Companies listed on BioPortfolio]

BeiGene (Beijing), Co., Ltd.

BeiGene is an innovative Chinese oncology R&D company focusing on discovering, developing and commercializing targeted and immune-oncology therapeutics. With a team of 150 scienti...

BeiGene Ltd.

BeiGene is an innovative, clinical-stage Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a no...

BeiGene, Ltd.

BeiGene is a Chinese life sciences biotechnology company based in the Zhongguancun Life Science Park in Beijing that is focused on discovering and developing innovative oncology d...

Beijing Med-Pharm Corp

Beijing Med-Pharm offers an end-to-end solution to U.S and western pharmaceutical companies wishing to sell their products in China. We offer sales and marketing services throughout China and can help...

Celgene Corporation and BeiGene, Ltd.

More Information about "BeiGene (Beijing), Co., Ltd." on BioPortfolio

We have published hundreds of BeiGene (Beijing), Co., Ltd. news stories on BioPortfolio along with dozens of BeiGene (Beijing), Co., Ltd. Clinical Trials and PubMed Articles about BeiGene (Beijing), Co., Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BeiGene (Beijing), Co., Ltd. Companies in our database. You can also find out about relevant BeiGene (Beijing), Co., Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record